Safety and efficacy of riluzole in patients undergoing decompressive surgery for degenerative cervical myelopathy (CSM-Protect): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial

Authors

Michael G. Fehlings, University of Toronto
Jetan H. Badhiwala, University of Toronto
Henry Ahn, University of Toronto
H Francis Farhadi, Ohio State University
Christopher I. Shaffrey, University of Virginia
Ahmad Nassr, Mayo Clinic
Praveen Mummaneni, University of California, San Francisco
Paul M. Arnold, Kansas University Medical Center
W Bradley Jacobs, University of Calgary
K Daniel Riew, Columbia University
Michael Kelly, Washington University in St Louis
Darrel S. Brodke, University of Utah
Alexander R. Vaccaro, Thomas Jefferson University
Alan S. Hilibrand, Thomas Jefferson University
Jason D. Wilson, LSUHSC New OrleansFollow

Document Type

Article

Publication Date

12-22-2020

Publication Title

Lancet Neurology

PubMed ID

33357512

Volume

20(2)

Recommended Citation

Fehlings, Michael G.; Badhiwala, Jetan H.; Ahn, Henry; Farhadi, H Francis; Shaffrey, Christopher I.; Nassr, Ahmad; Mummaneni, Praveen; Arnold, Paul M.; Jacobs, W Bradley; Riew, K Daniel; Kelly, Michael; Brodke, Darrel S.; Vaccaro, Alexander R.; Hilibrand, Alan S.; and Wilson, Jason D., "Safety and efficacy of riluzole in patients undergoing decompressive surgery for degenerative cervical myelopathy (CSM-Protect): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial" (2020). School of Medicine Faculty Publications. 1227.
https://digitalscholar.lsuhsc.edu/som_facpubs/1227